Vanguard Global Advisers
CAPR icon

Vanguard Global Advisers’s Capricor Therapeutics CAPR Stock Holding History

Vanguard Global Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$688K Buy
28,552
+4,193
+17% +$127K ﹤0.01% 1958
2026
Q1 		$741K Buy
+24,359
New +$649K ﹤0.01% 1813

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Global Advisers's CAPR Position: Q2 2026 in Review

Vanguard Global Advisers increased its Capricor Therapeutics (CAPR) stake by 17% in Q2 2026, buying an estimated $127K and bringing the position to 28,552 shares worth $688K. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Vanguard Global Advisers first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $741K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Vanguard Global Advisers held 28,552 shares of Capricor Therapeutics worth $688K as of Q2 2026.
  • Vanguard Global Advisers bought 4,193 Capricor Therapeutics shares in Q2 2026, an estimated $127K.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1958 holding.
  • Vanguard Global Advisers first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Capricor Therapeutics position peaked at $741K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.